GRIN2D

Glutamate receptor ionotropic, NMDA 2D · O15399 · GRIN2D on Sugi Atlas →

104,657 patent compounds predicted against GRIN2D, 60,156 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL123451	0.55	14/20
SCHEMBL121942	1.00	11/20
Guanabenz (SCHEMBL15390)	0.65	11/20
Memantine (SCHEMBL2688)	1.00	9/20
Memantine (SCHEMBL2689)	1.00	9/20
Memantine (SCHEMBL3053)	0.95	9/20
Levorphanol (SCHEMBL24335)	1.00	8/20
Racemorphan (SCHEMBL46201)	1.00	8/20
Dextrorphan (SCHEMBL115577)	1.00	8/20
SCHEMBL103596	0.44	8/20
Dextromethorphan (SCHEMBL29949)	1.00	7/20
Levomethorphan (SCHEMBL29950)	1.00	7/20
SCHEMBL78658	1.00	7/20
Radiprodil (SCHEMBL99256)	1.00	7/20
Racemethorphan (SCHEMBL118520)	1.00	7/20
Radiprodil (SCHEMBL134435)	0.98	7/20
Dextromethorphan (SCHEMBL121924)	0.98	7/20
Dextrorphan (SCHEMBL122564)	0.98	7/20
Dextromethorphan (SCHEMBL121923)	0.95	6/20

Clinical trials — most relevant to GRIN2D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
Dexmedetomidine Adjuvant Treatment for Depressed Patients Undergoing ECT	PHASE4	UNKNOWN
Ketamine Treatment Effects on Synaptic Plasticity in Depression	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Nuedexta in Treatment-Resistant Major Depression	PHASE2	COMPLETED
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis	nan	UNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia	nan	COMPLETED
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients	nan	COMPLETED
Early Psychosis: Investigating Cognition	nan	RECRUITING
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIN2D binder may also engage these)

Protein	Name	Similarity
Q03391	—	1.000	Q03391 →
Q62645	—	1.000	Q62645 →
Q8VHN2	—	0.985	Q8VHN2 →
Q91ZU9	—	0.982	Q91ZU9 →
GRIN3B	Glutamate receptor ionotropic, NMDA 3B (GluN3	0.981	landscape →
Q00961	—	0.965	Q00961 →
GRIN2C	Glutamate receptor ionotropic, NMDA 2C	0.964	landscape →
Q01098	—	0.956	Q01098 →
Q9R1M7	—	0.955	Q9R1M7 →
O09010	—	0.955	O09010 →
Q8NES3	—	0.954	Q8NES3 →
GRM6	Metabotropic glutamate receptor 6	0.953	landscape →
P35349	—	0.953	P35349 →
Q5NCH9	—	0.953	Q5NCH9 →
Q924T4	—	0.951	Q924T4 →
A2AIR5	—	0.950	A2AIR5 →
Q9HB15	—	0.950	Q9HB15 →
GRIN3A	Glutamate receptor ionotropic, NMDA 3A	0.949	landscape →
P23726	—	0.948	P23726 →
Q9P244	—	0.948	Q9P244 →
SMO	Protein smoothened	0.948	landscape →
Q2KJ92	—	0.948	Q2KJ92 →
Q9NRU3	—	0.947	Q9NRU3 →
Q5ZIW1	—	0.947	Q5ZIW1 →
Q863I4	—	0.947	Q863I4 →
P0C7J6	—	0.946	P0C7J6 →
B1ATG9	—	0.946	B1ATG9 →
D4ABX8	—	0.946	D4ABX8 →
Q6ZRP7	—	0.946	Q6ZRP7 →
O97583	—	0.945	O97583 →